Navigation Links
Misonix Reports Financial Results for First Half of Fiscal 2013
Date:2/7/2013

for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on
'/>"/>

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Misonix Presents at MicroCapClub Invitational
2. Misonix Terminates Distribution Agreement With Aesculap
3. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
4. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
5. Misonix Product Featured At Neurosurgery Congress
6. Misonix Adds 6 Spine Sales Agencies In The U.S.
7. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
8. Misonix Inks New Distribution Agreement For Croatia And Slovenia
9. Misonix And Soelim Create New Distribution Alliance For South Korea
10. Misonix Participates In Cleveland Spine Review
11. Misonix Adds Industry Veteran To Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... XRpro Sciences, Inc., a provider of ... services which features high throughput transporter and ion ... results for the year ended December 31, 2014. ... XRpro Sciences commented, "We have completed a number ... to commercial stage in large part by achieving ...
(Date:3/27/2015)... -- Report Details  New study ... What does the future hold for top ... brand new report shows you potential revenues to 2025, ... Our 242-page report provides 185 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
(Date:3/27/2015)... -- According to a new market research ... Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, ... - Global Forecasts to 2019 ", published by MarketsandMarkets, the ... Billion by 2019 with a CAGR of around 10.3% ... Browse   90   ma rket data ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... 2011 US-based Life Technologies Corporation (Nasdaq: ... science solutions, announced today that it has launched a ... demand in the Asia Pacific regions of India, China, ... New Zealand. (Logo:   http://photos.prnewswire.com/prnh/20110216/MM49339LOGO ) ...
... GlaxoSmithKline (NYSE: GSK ) today announced that ... full approval for PROMACTA® (eltrombopag), an oral tablet that ... blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who ... splenectomy. PROMACTA initially received FDA orphan ...
Cached Medicine Technology:Life Technologies Launches Asia Distribution Center in Singapore 2Life Technologies Launches Asia Distribution Center in Singapore 3Life Technologies Launches Asia Distribution Center in Singapore 4FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 2FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 3FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 4
(Date:3/29/2015)... March 29, 2015 “Health is an ... as we learn more about the cannabinoid system … ... March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ new ... endo-healing, is celebrated. Publius, of The Cannabis Papers: A ... Institutes of Health (PubMed) cannabinoid system (CS) articles discussing: ...
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
(Date:3/28/2015)... March 28, 2015 Emergency Medical Care ... care in Manhattan, recently commemorated its three-year anniversary of ... Manhattan. In addition to 24-hour urgent care, Emergency Medical ... , At this time, Emergency Medical Care’s Urgent ... asthma, chest pain, eye injuries, ear infections, fevers, insect ...
(Date:3/28/2015)... Chicago, IL (PRWEB) March 28, 2015 Centurion ... medical equipment auction on Thursday, April 2 at their Las ... Las Vegas, NV 89081. The sale, which consists of equipment ... will begin promptly at 9 a.m. PDT. , Buyers ... radiology and surgery equipment. “We are a one-stop-shop,” said Erik ...
Breaking Medicine News(10 mins):Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
... Fla., Feb. 26 John Williams,a shrimp fisherman ... today before the House Subcommittee on Oversight and,Investigations ... safety. Williams criticized the Food and Drug Administration,s,(FDA) ... recommended Congress,take legislative actions., "On behalf of ...
... Customers and ... Private Insurance Corporations, OAKLAND, Calif., Feb. 26 ... organized by the California,Nurses Association/National Nurses Organizing Committee that ... a,9/11 rescue worker; Donna Smith, who has recently joined ...
... 690, Hospital Reach Settlement on Outstanding Disputes, ... General Hospital in Sandpoint, Idaho reached settlement on ... of Local 690,in Spokane, Washington., "This settlement ... to,perform their jobs capably despite management,s refusal to ...
... connects, educates and entertains sports world, KANSAS ... a new,online hotspot with Kansas City roots. A ... produce AthletixNation.com, the premier,community for all athletes, fans, ... AthletixNation.com is to have a positive impact,on the ...
... announces the release,of two new lifts, and a campaign ... open, twin mast design, and the SARA Lite, a ... twin masts, which improve stability and weight,distribution, but also ... functions, including Powered DPS (Dynamic Positioning System),are controlled via ...
... - Michel de Rosen to Continue as Chairman of the Board ... B. Soland Promoted to Chief Operating Officer -, ... announced today that, effective March 31, 2008, Vincent J.,Milano will succeed ... and has been elected to its board of directors. Mr.,de Rosen, ...
Cached Medicine News:Health News:Testimony to Congress Denounces FDA Reliance on Self-Policing 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Nurses Convince Hospital to Return to Bargaining Table 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 3
... (IGF-II) is a 7.5 kDa peptide which is ... to have mitogenic and metabolic actions involved in ... by binding to target cell receptors. IGF-II binds ... receptor, a monomeric protein which also serves as ...
... growth factor II (IGF-II) is a 7.5 kDa ... and is postulated to have mitogenic and metabolic ... IGF-II are mediated by binding to target cell ... Type II IGF receptor, a monomeric protein which ...
... growth factor II (IGF-II) is a 7.5 kDa ... and is postulated to have mitogenic and metabolic ... IGF-II are mediated by binding to target cell ... Type II IGF receptor, a monomeric protein which ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
Medicine Products: